We discovered that anlotinib could successfully promote CD8+ T cells to break through the “immune barrier” of VEC-PD-L1, infiltrate tumor tissues and significantly increase the ratio of CD8/FoxP3 compared with control group. Here, CD8A is linked to neoplasm.